Physician profile
Tamim Ghith
NPI 1760658959
$3,630.35
in general payments reported to CMS, 2019-2025
26 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $221 · 2021: $305 · 2022: $515 · 2023: $234 · 2024: $776 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.20 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $322.35 | 2023-2025 | |
| Vifor Pharma, INC. | $320.35 | 2019-2022 | |
| Travere Therapeutics, INC. | $296.07 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.20 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $225.32 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $211.85 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $201.85 | 2022-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $188.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $184.33 | 2019-2023 | Ultomiris |
| Baxter Healthcare | $172.22 | 2019-2023 | Renal - Extraneal Solution |
| Aurinia Pharma U.S., INC. | $134.31 | 2021-2022 | |
| Novo Nordisk INC | $120.13 | 2025 | Wegovy |
| Vantive US Healthcare LLC | $104.46 | 2025 | Renal - Pd |
| Scpharmaceuticals INC. | $84.14 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.85 | 2020-2025 | |
| Amgen INC. | $59.43 | 2021-2024 | Tavneos |
| Ardelyx, INC. | $51.62 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $40.30 | 2023-2025 | Givlaari |
| Akebia Therapeutics INC | $37.53 | 2021-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $32.32 | 2025 | Acthar |
| Fresenius USA Marketing, INC. | $31.95 | 2024 | Velphoro |
| Daiichi Sankyo INC. | $22.14 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.54 | 2025 | Empaveli |
| Lilly USA, LLC | $16.90 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamim Ghith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.